Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
November 14, 2024 16:30 ET
|
Exagen Inc.
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 13, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following...
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024 08:00 ET
|
Exagen Inc.
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD,...
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
October 29, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024,...
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
October 21, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College...
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
September 04, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global...
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
August 05, 2024 08:00 ET
|
Exagen Inc.
CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30,...
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 02, 2024 09:00 ET
|
Exagen Inc.
CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th...
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
August 01, 2024 09:00 ET
|
Exagen Inc.
CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of...
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
July 22, 2024 09:00 ET
|
Exagen Inc.
CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before...